G

Galderma Group AG
SIX:GALD

Watchlist Manager
Galderma Group AG
SIX:GALD
Watchlist
Price: 97 CHF 0.83%
Market Cap: 23B CHF
Have any thoughts about
Galderma Group AG?
Write Note

Galderma Group AG
Accumulated Depreciation

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Galderma Group AG
Accumulated Depreciation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accumulated Depreciation CAGR 3Y CAGR 5Y CAGR 10Y
G
Galderma Group AG
SIX:GALD
Accumulated Depreciation
-246.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Transocean Ltd
NYSE:RIG
Accumulated Depreciation
-$6.4B
CAGR 3-Years
-3%
CAGR 5-Years
-4%
CAGR 10-Years
3%
S
Sealsq Corp
NASDAQ:LAES
Accumulated Depreciation
-$13.1m
CAGR 3-Years
-7%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
T
TalkPool AG
STO:TALK
Accumulated Depreciation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
R
R&S Group Holding AG
SIX:RSGN
Accumulated Depreciation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Galderma Group AG
Glance View

Market Cap
23B CHF
Industry
N/A

Galderma Group AG, a prominent player in the dermatological field, has carved a niche for itself since its inception in 1981 as a joint venture between Nestlé and L'Oréal. Now operating independently, Galderma journeys through the complex terrain of skin health, focusing keenly on prescription drugs, over-the-counter products, and aesthetics medicine. Its spectrum of offerings spans across dermatology segments—from treating acne and rosacea to pioneering advances in aesthetic treatments with its products like Restylane and Dysport. The company's core strategy revolves around leveraging its extensive R&D capabilities, ensuring that medical and aesthetic practitioners have cutting-edge solutions that address both therapeutic and enhancement demands. Revenue streams for Galderma primarily flow from its three business pillars—prescription, aesthetics, and consumer health solutions. The prescription segment engages dermatologists and healthcare providers, offering topicals and oral medications pivotal for serious skin conditions. The aesthetics division appeals to clinics and practitioners focusing on beauty and corrective procedures, while consumer health offers OTC solutions direct to customers for daily skin concerns. Galderma capitalizes on strategic alliances and partnerships, ensuring robust distribution channels, and invests heavily in innovation, staying at the forefront of the fast-evolving dermatology landscape. With a presence in over 100 countries, Galderma has made a mark by blending medical rigor with consumer accessibility, anchoring its success in its in-depth understanding of skin health and nuanced market needs.

GALD Intrinsic Value
Not Available
G

See Also

What is Galderma Group AG's Accumulated Depreciation?
Accumulated Depreciation
-246.2m

Based on the financial report for Dec 31, 2023, Galderma Group AG's Accumulated Depreciation amounts to -246.2m .

What is Galderma Group AG's Accumulated Depreciation growth rate?
Accumulated Depreciation CAGR 1Y
-13%

Over the last year, the Accumulated Depreciation growth was -13%.

Back to Top